Iomedico Ag
Clinical trials sponsored by Iomedico Ag, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- 1000 liver cancer patients enrolled in nationwide registry study Results expected Sep 2026 (estimated)
- New study tracks quality of life in myeloma patients on selinexor combo Results expected Oct 2026 (estimated)
- Massive myeloma registry launched to map Real-World treatments Results expected Dec 2026 (estimated)
-
1000 liver cancer patients enrolled in nationwide registry study
Knowledge-focused OngoingThe JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Real-World data registry aims to map best treatment paths for advanced colorectal cancer
Knowledge-focused OngoingThis registry tracks adults with metastatic colorectal cancer who are starting their first systemic therapy. Researchers will collect information on the treatments doctors choose, how well they work, and patients' quality of life. The goal is to understand what happens in everyda…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New study tracks quality of life in myeloma patients on selinexor combo
Knowledge-focused OngoingThis observational study follows 75 people with relapsed or refractory multiple myeloma who are already taking selinexor combined with bortezomib and dexamethasone. Researchers will track quality of life, side effects, and how the treatment works in everyday medical practice. The…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC